Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Global initiative for asthma (GINA) 2019 recommends adding a long-acting β-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma. Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients.
Objective: This phase III QUARTZ was a multicentre, randomised, double-blind, double-dummy and parallel-group study to assess the efficacy and safety of low-dose IND/MF 150/80 μg once daily (o.d.) versus MF 200 μg o.d. in adult and adolescent patients with inadequately controlled asthma.
Methods: Eligible patients (n = 802) were randomised (1:1) to receive either low-dose IND/MF 150/80 μg o.d. via Breezhaler® or MF 200 μg o.d. via Twisthaler® for 12 weeks. Primary endpoint was trough forced expiratory volume in 1 s (FEV) and key secondary endpoint was Asthma Control Questionnaire (ACQ-7) treatment difference after 12-week treatment. Other secondary endpoints included ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, evaluated over 12-week treatment. Safety was also assessed including serious asthma outcomes.
Results: Low-dose IND/MF significantly improved trough FEV (least squares mean treatment difference [LSMTD]: 0.182 L; p < 0.001) and ACQ-7 (LSMTD: -0.218; p < 0.001) versus MF at Week 12. Improvements in all other secondary endpoints favoured low-dose IND/MF. Safety was comparable.
Conclusion: These results support the use of low-dose IND/MF 150/80 μg o.d. as a potential therapy for adult and adolescent patients with inadequately controlled asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2019.105809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges, benefits, and strategies for delivering pregnancy care to people with disabilities: A qualitative study of service providers and decision-makers in Ontario, Canada.
J Health Serv Res Policy
September 2025
Department of Health and Society, University of Toronto Scarborough, Toronto, ON, Canada.
ObjectivesTo (1) understand the challenges and benefits of providing pregnancy care to people with disabilities and (2) identify strategies to address challenges, from the perspectives of health care and social service providers and decision-makers.MethodsWe undertook a qualitative descriptive study in Ontario, Canada, of 31 health care and social service providers and decision-makers. Participants completed semi-structured interviews about their education, training, and clinical or administrative experience working with pregnant and/or parenting people with physical, sensory, and intellectual or developmental disabilities, including challenges and benefits in pregnancy care provision, programming, and policies, as well as their recommendations to improve care.
View Article and Find Full Text PDFSerum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
Lancet Rheumatol
September 2025
Bristol Royal Hospital for Children and Translational Health Sciences, Bristol, UK. Electronic address:
Background: Baricitinib has previously been shown to improve clinical response in patients with juvenile idiopathic arthritis (JIA) in the JUVE-BASIS trial. In this post-hoc analysis we aimed to identify whether pharmacodynamic changes in serum biomarkers in response to baricitinib treatment could help reaffirm the clinical utility of baricitinib in patients with JIA.
Methods: JUVE-BASIS was a randomised, double-blind, placebo-controlled, withdrawal, efficacy, safety, phase 3 trial, done in 75 centres in 20 countries.
[Functional neurological disorders: history and current situation].
Rev Infirm
September 2025
Centre bipol-AIR, 9 rue Abraham-Bloch, 69007 Lyon, France.
Functional neurological disorders are characterized by a variety of neurological symptoms that are not explained by an identifiable organic pathology. Despite their significant prevalence and major impact on quality of life, their recognition and management remain inadequate. Formerly known as hysteria, modern criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-5]) allow a positive diagnosis, distinct from malingering.
View Article and Find Full Text PDFThe interplay between sleep and neural respiratory drive in COPD: contribution of semi-automated analysis of long duration recordings.
Neuroimage
September 2025
UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, INSERM, Sorbonne Université, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Département R3S, Paris, France. Electronic address:
Background: Neural respiratory drive (NRD) is a clinically relevant biomarker in patients with chronic obstructive pulmonary disease (COPD). However, its analysis is challenging due to several technical considerations, including the need to obtain a stable recording over a short time period. However, a short recording duration may be inadequate to comprehensively record clinically relevant information, particularly during sleep, because NRD varies across sleep stages and over time.
View Article and Find Full Text PDFPatient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study.
Curr Med Res Opin
September 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Objectives: In ENGAGE, patients with major depressive disorder (MDD) demonstrated improvements in patient-reported depression and life engagement while taking adjunctive brexpiprazole. This analysis aimed to further characterize patient perspectives on the effects of adjunctive brexpiprazole, using patient diary data from ENGAGE, and describe development of a 'word of the day' activity.
Methods: Prior to ENGAGE, word lists describing a 'good,' 'average,' and 'bad' day with depression were generated from semi-structured interviews with patients with MDD.